ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome. Issue 2 (24th December 2019)

• Record Type: Journal Article
• Authors: Drexel, Heinz; Coats, Andrew J S; Spoletini, Ilaria; Bilato, Claudio; Mollace, Vincenzo; Perrone Filardi, Pasquale; Rosano, Giuseppe M C
• Is Part Of: European heart journal. Volume 6:Issue 2(2020)
• Page Start: 115
• Page End: 121
• Publication Date: 2019-12-24
• Subjects: Statins adherence -- Statin intolerance -- Low-density lipoprotein cholesterol -- Ezetimibe -- PCSK9 inhibitors -- Position paper; Cardiovascular pharmacology -- Periodicals; 615.71
• DOI: 10.1093/ehjcvp/pvz079
• Languages: English
• ISSNs: 2055-6837

Abstract

Abstract: Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the European Society of Cardiology in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.